Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

SCNH2 is a novel apelinergic family member acting as a potent mitogenic and chemotactic factor for both endothelial and epithelial cells.

Fang C, Avis I, Bianco C, Held N, Morris J, Ylaya K, Hewitt SM, Aplin AC, Nicosia RF, Fung LA, Lewis JD, Stetler-Stevenson WG, Salomon DS, Cuttitta F.

Open J Clin Diagn. 2013 Jun;3(2):37-51.

2.

Novel Phenotypic Fluorescent Three-Dimensional Platforms for High-throughput Drug Screening and Personalized Chemotherapy.

Fang C, Avis I, Salomon D, Cuttitta F.

J Cancer. 2013 Jun 26;4(5):402-15. doi: 10.7150/jca.6780. Print 2013.

3.

Non-peptide small molecule regulators of lymphangiogenesis.

Fang C, Miguel MA, Avis I, Martinez A, Zudaire E, Cuttitta F.

Lymphat Res Biol. 2009 Dec;7(4):189-96. doi: 10.1089/lrb.2009.0033.

4.

Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886.

Mayburd AL, Martlínez A, Sackett D, Liu H, Shih J, Tauler J, Avis I, Mulshine JL.

Clin Cancer Res. 2006 Mar 15;12(6):1820-7.

5.

Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.

Avis I, Martínez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL.

Cancer Res. 2005 May 15;65(10):4181-90.

6.

Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.

Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF Jr.

Clin Cancer Res. 2004 Mar 1;10(5):1565-73.

7.

Moving to the routine management of pre symptomatic lung cancer.

Mulshine JL, Hong S, Martínez A, Tauler J, Avis I, Tockman MS, De Luca LM, Placke ME, Cuttitta F.

Lung Cancer. 2001 Dec;34 Suppl 2:S1-5.

PMID:
11720735
8.

Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions.

Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL.

FASEB J. 2001 Sep;15(11):2007-9. Epub 2001 Jul 9.

PMID:
11511519
9.

Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer.

Zhou J, Allred DC, Avis I, Martínez A, Vos MD, Smith L, Treston AM, Mulshine JL.

Breast Cancer Res Treat. 2001 Apr;66(3):217-24.

PMID:
11510693
10.

Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations.

Man YG, Martinez A, Avis IM, Hong SH, Cuttitta F, Venzon DJ, Mulshine JL.

Am J Respir Cell Mol Biol. 2000 Nov;23(5):636-45.

PMID:
11062142
11.

Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?

Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF Jr, Van Waes C, Mulshine JL.

FASEB J. 2000 Aug;14(11):1499-507.

PMID:
10928984
12.

Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.

Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulshine JL.

Clin Cancer Res. 1999 Nov;5(11):3385-93.

13.
14.

Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development.

Montuenga LM, Zhou J, Avis I, Vos M, Martinez A, Cuttitta F, Treston AM, Sunday M, Mulshine JL.

Am J Respir Cell Mol Biol. 1998 Oct;19(4):554-62.

PMID:
9761751
15.

Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers.

Zhou J, Mulshine JL, Ro JY, Avis I, Yu R, Lee JJ, Morice R, Lippman SM, Lee JS.

Clin Cancer Res. 1998 Jul;4(7):1631-40.

16.

Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer.

Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, Johnson BE.

Chest. 1997 Jul;112(1):256-61.

PMID:
9228385
17.

Recent molecular advances in the approach to early lung cancer detection and intervention.

Mulshine JL, Scott F, Zhou J, Avis I, Vos M, Treston AM.

Environ Health Perspect. 1997 Jun;105 Suppl 4:935-9. Review.

18.

Peptide amidating activity in human bronchoalveolar lavage fluid.

Scott FM, Treston AM, Shaw GL, Avis I, Sorenson J, Kelly K, Dempsey EC, Cantor AB, Tockman M, Mulshine JL.

Lung Cancer. 1996 Jun;14(2-3):239-51.

PMID:
8794407
20.

Development of Molecular Approaches to Early Lung Cancer Detection.

Mulshine JL, Scott F, Zhou J, Avis I I, Vos M, Miller MJ, Szabo E, Martinez A, Treston AM, Cuttitta F, Tockman M.

Semin Radiat Oncol. 1996 Apr;6(2):72-75.

PMID:
10717164
21.

Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling.

Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martínez A, Mulshine JL.

J Clin Invest. 1996 Feb 1;97(3):806-13.

22.

Transferrin dependence of Ga (NO3)3 inhibition of growth in human-derived small cell lung cancer cells.

Weiner RE, Avis I, Neumann RD, Mulshine JL.

J Cell Biochem Suppl. 1996;24:276-87.

PMID:
8806110
23.

Analysis of small cell lung cancer cell growth inhibition by 13-cis-retinoic acid: importance of bioavailability.

Avis I, Mathias A, Unsworth EJ, Miller MJ, Cuttitta F, Mulshine JL, Jakowlew SB.

Cell Growth Differ. 1995 May;6(5):485-92.

24.

Scientific basis for cancer prevention. Intermediate cancer markers.

Mulshine JL, Jett M, Cuttitta F, Treston AM, Quinn K, Scott F, Iwai N, Avis I, Linnoila RI, Shaw GL.

Cancer. 1993 Aug 1;72(3 Suppl):978-83. Review.

PMID:
8334673
25.

Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage.

Scott F, Cuttitta F, Treston AM, Avis I, Gupta P, Ruckdeschel J, Kelly K, Piantadosi S, Tockman M, Mulshine J.

J Cell Biochem Suppl. 1993;17F:175-83.

PMID:
8412189
26.

Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan).

Avis I, Jett M, Kasprzyk PG, Cuttitta F, Treston AM, Maneckjee R, Mulshine JL.

Mol Carcinog. 1993;8(4):214-20.

PMID:
8280369
27.

The correct dose: pharmacologically guided end point for anti-growth factor therapy.

Mulshine JL, Shuke N, Daghighian F, Carrasquillo J, Ghosh B, Walsh T, Avis I, Reynolds JC, Cuttitta F, Larson SM.

Cancer Res. 1992 May 1;52(9 Suppl):2743s-2746s.

28.

Candidate biomarkers for application as intermediate end points of lung carcinogenesis.

Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJ, et al.

J Cell Biochem Suppl. 1992;16G:183-6. Review.

PMID:
1469899
29.

Growth factors and other targets for rational application as intervention agents.

Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F.

Adv Exp Med Biol. 1992;320:81-8. Review. No abstract available.

PMID:
1442286
30.

Rational targets for the early detection of lung cancer.

Mulshine JL, Linnoila RI, Jensen SM, Magnani JL, Tockman MS, Gupta PK, Scott FS, Avis I, Quinn K, Birrer MJ, et al.

J Natl Cancer Inst Monogr. 1992;(13):183-90. Review.

PMID:
1389692
31.

Alpha-amidation of peptide hormones in lung cancer.

Quinn KA, Treston AM, Scott FM, Kasprzyk PG, Avis I, Siegfried JM, Mulshine JL, Cuttitta F.

Cancer Cells. 1991 Dec;3(12):504-10. Review.

PMID:
1668141
32.

Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer.

Avis IL, Kovacs TO, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL.

J Natl Cancer Inst. 1991 Oct 16;83(20):1470-6.

PMID:
1656058
33.

Lung cancer: rational strategies for early detection and intervention.

Mulshine JL, Treston AM, Scott FM, Avis I, Boland C, Phelps R, Kasprzyk PG, Nakanishi Y, Cuttitta F.

Oncology (Williston Park). 1991 May;5(5):25-32; discussion 32-3, 37.

PMID:
1832003
34.

[Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo.

Mahmoud S, Staley J, Taylor J, Bogden A, Moreau JP, Coy D, Avis I, Cuttitta F, Mulshine JL, Moody TW.

Cancer Res. 1991 Apr 1;51(7):1798-802.

35.

Autocrine growth factors as therapeutic targets in lung cancer.

Mulshine JL, Treston AM, Natale RB, Kasprzyk PG, Avis I, Nakanishi Y, Cuttitta F.

Chest. 1989 Jul;96(1 Suppl):31S-34S. Review. No abstract available.

PMID:
2661168
36.

Autocrine growth factors and lung cancer.

Mulshine JL, Natale RB, Avis I, Treston AM, Kasprzyk PG, Nakanishi Y, Sausville EA, Trepel JB, Cuttitta F.

Cancer Treat Res. 1989;45:107-22. Review. No abstract available.

PMID:
2577167
37.

In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung.

Mulshine JL, Avis I, Treston AM, Kaspryzyk PG, Nakanishi Y, Mobley C, Carrasquillo JA, Larson SM, Merchant B, Cuttitta F.

Int J Rad Appl Instrum B. 1989;16(2):159-62. Review.

PMID:
2541112
38.

Solid-phase peptide quantitation assay using labeled monoclonal antibody and glutaraldehyde fixation.

Kasprzyk PG, Cuttitta F, Avis I, Nakanishi Y, Treston A, Wong H, Walsh JH, Mulshine JL.

Anal Biochem. 1988 Oct;174(1):224-34.

PMID:
3146232
39.

Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.

Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F.

J Clin Invest. 1988 Jul;82(1):354-9.

40.

Consideration of the chemistry of solid-phase matrix interaction leads to improved quantitation of neuropeptides.

Kasprzyk PG, Cuttitta F, Treston AM, Avis I, Nakanishi Y, Wong H, Walsh JH, Mulshine JL.

Ann N Y Acad Sci. 1988;547:41-53. No abstract available.

PMID:
3239893
41.

Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer.

Mulshine JL, Avis I, Treston AM, Mobley C, Kaspryzyk P, Carrasquillo JA, Larson SM, Nakanishi Y, Merchant B, Minna JD, et al.

Ann N Y Acad Sci. 1988;547:360-72. No abstract available.

PMID:
2853598
42.

Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth?

Nakanishi Y, Cuttitta F, Kasprzyk PG, Avis I, Steinberg SM, Gazdar AF, Mulshine JL.

Exp Cell Biol. 1988;56(1-2):74-85.

PMID:
2846378
44.

Blood group A-like activity in a long-term renal cell line.

Leet DC, Kuhns WJ, Avis I, Avis FP.

Invest Urol. 1980 Jan;17(4):305-9.

PMID:
7351362
45.

Certain aspects of analysis of complement dependent antibody in breast cancer patients.

Hindsley JP Jr, Avis I, Newsome JF, Fried FA, Avis FP.

J Surg Oncol. 1979;11(2):107-27.

PMID:
439897
46.

Transplantation of human prostate neoplasia into the nude mouse.

Hindsley JP Jr, Fried FA, Avis I, Avis FP.

Natl Cancer Inst Monogr. 1978 Dec;(49):67-9.

PMID:
86170
47.

Cell-mediated immunity in renal cell carcinoma-preliminary report.

Cole AT, Avis I, Fried FA, Avis F.

J Urol. 1976 Mar;115(3):234-8.

PMID:
1255881
48.

Antigenic cross-reactivity between adenocarcinoma of the breast and fibrocystic disease of the breast.

Avis F, Avis I, Newsome JF, Haughton G.

J Natl Cancer Inst. 1976 Jan;56(1):17-25.

PMID:
1255745
49.

Antigenic cross reactivity between benign prostatic hyperplasia and adenocarcinoma of prostate.

Avis F, Avis I, Cole AT, Fried F, Haughton G.

Urology. 1975 Jan;5(1):122-30.

PMID:
1114533

Supplemental Content

Support Center